

MERIDIAN BIOSCIENCE INC

Form 10-Q

February 09, 2011

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
Form 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the Quarterly Period Ended December 31, 2010**

**OR**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission file number 0-14902**

**MERIDIAN BIOSCIENCE, INC.**

Incorporated under the laws of Ohio

31-0888197

(I.R.S. Employer Identification No.)

3471 River Hills Drive

Cincinnati, Ohio 45244

(513) 271-3700

Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Outstanding January 31, 2011
Common Stock, no par value	40,968,750

**MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES  
INDEX TO QUARTERLY REPORT ON FORM 10-Q**

	<b>Page(s)</b>
<b><u>PART I. FINANCIAL INFORMATION</u></b>	
<b><u>Item 1. Financial Statements (Unaudited)</u></b>	
<u>Condensed Consolidated Statements of Operations</u> <u>Three Months Ended December 31, 2010 and 2009</u>	1
<u>Condensed Consolidated Statements of Cash Flows</u> <u>Three Months Ended December 31, 2010 and 2009</u>	2
<u>Condensed Consolidated Balance Sheets</u> <u>December 31, 2010 and September 30, 2010</u>	3-4
<u>Condensed Consolidated Statement of Changes in Shareholders' Equity</u> <u>Three Months Ended December 31, 2010</u>	5
<u>Notes to Condensed Consolidated Financial Statements</u>	6-12
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	12-18
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	18
<u>Item 4. Controls and Procedures</u>	18
<b><u>PART II. OTHER INFORMATION</u></b>	
<u>Item 1A. Risk Factors</u>	19
<u>Item 6. Exhibits</u>	19
<u>Signature</u>	20
<u>Exhibit 10.18.3</u>	
<u>Exhibit 31.1</u>	
<u>Exhibit 31.2</u>	
<u>Exhibit 32</u>	
<u>EX-101 INSTANCE DOCUMENT</u>	
<u>EX-101 SCHEMA DOCUMENT</u>	
<u>EX-101 CALCULATION LINKBASE DOCUMENT</u>	
<u>EX-101 LABELS LINKBASE DOCUMENT</u>	
<u>EX-101 PRESENTATION LINKBASE DOCUMENT</u>	
<u>EX-101 DEFINITION LINKBASE DOCUMENT</u>	

*The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as "estimates", "anticipates", "projects", "plans", "seeks", "may", "will", "expects", "intends", "believes", "should" and*

*similar expressions or the negative versions thereof and which also may be identified by their context. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian's continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian's competition. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers can change expected results. Costs and difficulties in complying with laws and regulations administered by the United States Food and Drug Administration can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. Changes in the relative strength or weakness of the U.S. dollar can also change expected results. One of Meridian's main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian's operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian's ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. The Company cannot predict the possible impact of recently-enacted United States healthcare legislation and any similar initiatives in other countries on its results of operations. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.*

---

**Table of Contents**

**Item 1. Financial Statements**  
**MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Statements of Operations (Unaudited)**  
**(in thousands, except per share data)**

<b>Three Months Ended December 31,</b>	<b>2010</b>	<b>2009</b>
NET SALES	\$ 37,263	\$ 42,457
COST OF SALES	13,643	16,972
GROSS PROFIT	23,620	25,485
OPERATING EXPENSES		
Research and development	2,328	2,078
Selling and marketing	5,687	4,887
General and administrative	6,515	4,764
Total operating expenses	14,530	11,729
OPERATING INCOME	9,090	13,756
OTHER INCOME (EXPENSE)		
Interest income	17	31
Other, net	203	(118)
Total other income (expense)	220	(87)
EARNINGS BEFORE INCOME TAXES	9,310	13,669
INCOME TAX PROVISION	3,285	4,748
NET EARNINGS	\$ 6,025	\$ 8,921
BASIC EARNINGS PER COMMON SHARE	\$ 0.15	\$ 0.22
DILUTED EARNINGS PER COMMON SHARE	\$ 0.15	\$ 0.22
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING BASIC	40,615	40,496
EFFECT OF DILUTIVE STOCK OPTIONS	679	689
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING DILUTED	41,294	41,185

ANTI-DILUTIVE SECURITIES:

Common share options	160	141
----------------------	-----	-----

DIVIDENDS DECLARED PER COMMON SHARE	\$ 0.19	\$ 0.17
-------------------------------------	---------	---------

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Table of Contents**

**MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Statements of Cash Flows (Unaudited)**  
**(dollars in thousands)**

<b>Three Months Ended December 31,</b>	<b>2010</b>	<b>2009</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Net earnings	\$ 6,025	\$ 8,921
Non-cash items:		
Depreciation of property, plant and equipment	845	762
Amortization of intangible assets	595	395
Stock-based compensation	967	559
Deferred income taxes	(955)	(431)
Loss on disposition of fixed assets	4	
Unrealized loss on auction-rate securities and rights, net		15
Change in current assets	2,276	6,194
Change in current liabilities	3,177	(3,282)
Other, net	665	37
 Net cash provided by operating activities	 13,599	 13,170
 <b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchases of property, plant and equipment	(2,559)	(880)
Purchases of intangibles and other assets	(12)	
Purchases of short-term investments		(1,000)
 Net cash used for investing activities	 (2,571)	 (1,880)
 <b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Dividends paid	(7,720)	(6,885)
Proceeds and tax benefits from exercises of stock options	739	96
 Net cash used for financing activities	 (6,981)	 (6,789)
 Effect of Exchange Rate Changes on Cash and Equivalents	 (447)	 (71)
 Net Increase in Cash and Equivalents	 3,600	 4,430
 Cash and Equivalents at Beginning of Period	 37,879	 54,030
 Cash and Equivalents at End of Period	 \$ 41,479	 \$ 58,460

The accompanying notes are an integral part of these condensed consolidated financial statements.





**Table of Contents**

**MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Balance Sheets (Unaudited)**  
**(dollars in thousands)**

**ASSETS**

	<b>December 31, 2010</b>	<b>September 30, 2010</b>
<b>CURRENT ASSETS</b>		
Cash and equivalents	\$ 41,479	\$ 37,879
Accounts receivable, less allowances of \$152 and \$241	20,278	22,064
Inventories	28,711	27,965
Prepaid expenses and other current assets	2,679	4,277
Deferred income taxes	2,041	1,871
Total current assets	95,188	94,056
<b>PROPERTY, PLANT AND EQUIPMENT, at Cost</b>		
Land	987	991
Buildings and improvements	20,849	20,670
Machinery, equipment and furniture	32,845	31,945
Construction in progress	4,126	2,800
Subtotal	58,807	56,406
Less: accumulated depreciation and amortization	34,418	33,689
Net property, plant and equipment	24,389	22,717
<b>OTHER ASSETS</b>		
Goodwill	22,755	23,025
Other intangible assets, net	12,590	13,327
Restricted cash	1,000	1,000
Other assets	246	239
Total other assets	36,591	37,591
<b>TOTAL ASSETS</b>	<b>\$ 156,168</b>	<b>\$ 154,364</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Table of Contents**

**MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Balance Sheets (Unaudited)**  
**(dollars in thousands)**  
**LIABILITIES AND SHAREHOLDERS' EQUITY**

	<b>December 31, 2010</b>	<b>September 30, 2010</b>
<b>CURRENT LIABILITIES</b>		
Accounts payable	\$ 5,183	\$ 4,466
Accrued employee compensation costs	4,310	3,451
Other accrued expenses	5,150	5,521
Income taxes payable	2,842	809
Total current liabilities	17,485	14,247
DEFERRED INCOME TAXES	2,131	2,756
<b>COMMITMENTS AND CONTINGENCIES</b>		
<b>SHAREHOLDERS' EQUITY</b>		
Preferred stock, no par value, 1,000,000 shares authorized, none issued		
Common shares, no par value, 71,000,000 shares authorized, 40,960,986 and 40,654,286 shares issued, respectively		
Additional paid-in capital	96,026	94,529
Retained earnings	40,482	42,177
Accumulated other comprehensive income	44	655
Total shareholders' equity	136,552	137,361
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b>\$ 156,168</b>	<b>\$ 154,364</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

**MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Statement of Changes in Shareholders Equity (Unaudited)**  
**(dollars and shares in thousands)**

	Common Shares	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	<i>Comprehensive Income (Loss)</i>	Total Shareholders Equity
<b>Balance at September 30, 2010</b>	40,654	\$ 94,529	\$ 42,177	\$ 655		\$ 137,361
Cash dividends paid			(7,720)			(7,720)
Exercise of stock options	119	530				530
Issuance of restricted shares	188					
Stock compensation expense		967				967
Comprehensive income:						
Net earnings			6,025		\$ 6,025	6,025
Foreign currency translation adjustment				(936)	(936)	(936)
Other comprehensive income taxes				325	325	325
Comprehensive income					\$ 5,414	
<b>Balance at December 31, 2010</b>	40,961	\$ 96,026	\$ 40,482	\$ 44		\$ 136,552

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Table of Contents**

**MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES**  
**Notes to Condensed Consolidated Financial Statements**  
**Dollars in Thousands, Except Per Share Amounts**  
**(Unaudited)**

**1. Basis of Presentation**

The interim condensed consolidated financial statements are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, and the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of Management, the interim financial statements include all normal adjustments and disclosures necessary to present fairly the Company's financial position as of December 31, 2010, the results of its operations for the three month periods ended December 31, 2010 and 2009, and its cash flows for the three month periods ended December 31, 2010 and 2009. These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company's fiscal 2010 Annual Report on Form 10-K. Financial information as of September 30, 2010 has been derived from the Company's audited consolidated financial statements.

The results of operations for interim periods are not necessarily indicative of the results to be expected for the year.

**2. Significant Accounting Policies**

**(a) *Revenue Recognition and Accounts Receivable***

Revenue is generally recognized from sales when product is shipped and title has passed to the buyer. Revenue for the U.S. Diagnostics operating segment is reduced at the date of sale for estimated rebates that will be claimed by customers. Management estimates accruals for rebate agreements based on historical statistics, current trends, and other factors. Changes to the accruals are recorded in the period that they become known. Our rebate accruals were \$5,276 at December 31, 2010 and \$5,273 at September 30, 2010.

Life Science revenue for contract services may come from research and development services or manufacturing services, including process development work, or a combination of both. Revenue is recognized based on each of the deliverables in a given arrangement having distinct and separate customer pricing. Pricing is often subject to a competitive bidding process. Contract research and development services may be performed on a time and materials basis or fixed fee basis. For time and materials arrangements, revenue is recognized as services are performed and billed. For fixed fee arrangements, revenue is recognized upon completion and acceptance by the customer. For contract manufacturing services, revenue is generally recognized upon delivery of product and acceptance by the customer. In some cases, customers may request that we store on their behalf clinical grade biologicals that we produce under contract manufacturing agreements. These cases arise when customers do not have clinical grade storage facilities or do not want to risk contamination during transport. For such cases, revenue may be recognized on a bill-and-hold basis.

Trade accounts receivable are recorded in the accompanying Condensed Consolidated Balance Sheets at invoiced amounts less provisions for rebates and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on historical write-off experience. The allowance for doubtful accounts and related metrics, such as days sales outstanding, are reviewed monthly. Accounts with past due balances over 90 days are reviewed individually for collectibility. Customer invoices are charged off against the allowance when we believe it is probable that the invoices will not be paid.

**Table of Contents****(b) Comprehensive Income (Loss)**

Our comprehensive income or loss is comprised of net earnings, foreign currency translation and the related income tax effects.

Assets and liabilities of foreign operations are translated using period-end exchange rates with gains or losses resulting from translation included as a separate component of comprehensive income or loss. Revenues and expenses are translated using exchange rates prevailing during the period. We also recognize foreign currency transaction gains and losses on certain assets and liabilities that are denominated in the Australian dollar, British pound and Euro currencies. These gains and losses are included in other income and expense in the accompanying Condensed Consolidated Statements of Operations.

Comprehensive income for the interim periods was as follows:

	<b>Three Months Ended December 31,</b>	
	<b>2010</b>	<b>2009</b>
Net earnings	\$ 6,025	\$ 8,921
Foreign currency translation adjustment	(936)	(257)
Income taxes	325	89
Comprehensive income	\$ 5,414	\$ 8,753

**(c) Income Taxes**

The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between income for financial reporting and income for tax purposes.

We prepare estimates of permanent and temporary differences between income for financial reporting purposes and income for tax purposes. These differences are adjusted to actual upon filing of our tax returns, typically occurring in the third and fourth quarters of the current fiscal year for the preceding fiscal year's estimates.

We account for uncertain tax positions using a benefit recognition model with a two-step approach: (i) a more-likely-than-not recognition criterion; and (ii) a measurement attribute that measures the position as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. If it is not more likely than not that the benefit will be sustained on its technical merits, no benefit is recorded. We recognize accrued interest and penalties related to unrecognized tax benefits as a portion of our income tax provision in the Condensed Consolidated Statements of Operations.

**(d) Stock-based Compensation**

We recognize compensation expense for all stock-based awards made to employees, based upon the fair value of the stock-based award on the date of the grant. Shares are expensed over their requisite service period.

**Table of Contents****(e) Cash, Cash Equivalents and Investments**

Our investment portfolio includes the following components:

	December 31, 2010		September 30, 2010	
	Cash and Equivalents	Other	Cash and Equivalents	Other
Taxable investments				
Overnight repurchase agreements	\$ 19,047	\$	\$ 14,862	\$
Money market funds	10,254		10,249	
Cash on hand				
Restricted		1,000		1,000
Unrestricted	12,178		12,768	
Total	\$ 41,479	\$ 1,000	\$ 37,879	\$ 1,000

**(f) Reclassifications**

Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation.

**3. Acquisition of Bioline Group**

On July 20, 2010, we acquired all of the outstanding common stock of the Bioline group of companies (collectively the Bioline Group). We paid \$23,849 from cash and equivalents on hand to acquire the Bioline Group. Headquartered in London, England, the Bioline Group is a leading manufacturer and distributor of molecular biology reagents with additional operations in Germany, Australia and the United States. The highly specialized molecular biology reagents it supplies to the life science research, biotech, pharmaceutical and commercial diagnostics markets are the critical components used in PCR testing for DNA, RNA and other genomic testing.

As a result of the consideration paid exceeding the fair value of the net assets being acquired, goodwill in the amount of \$12,725 was recorded in connection with this acquisition, none of which will be deductible for tax purposes. This goodwill results largely from the addition of key global operations and direct sales capabilities, management talent and a research-oriented customer base, to complement our existing Life Science operations. In addition to the Bioline Group's results of operations, which are included in our Condensed Consolidated Statement of Operations for the three months ended December 31, 2010 and reported as part of the Life Science operating segment, the consolidated results for the three months ended December 31, 2010 also include:

- i) \$350 of Cost of Sales related to the roll-out of fair value inventory adjustments for sales of products that were in the Bioline Group's inventory on the date of acquisition and, therefore, were valued at fair value, rather than manufactured cost, in the opening balance sheet; and
- ii) \$252 of General and Administrative Expenses related to the amortization of specific identifiable intangible assets recorded on the opening balance sheet, including customer relationships, license agreements, non-compete agreements, manufacturing processes and trade names.

The results of the Bioline Group included in the consolidated results of the Company for the three months ended December 31, 2010 are Net Sales of \$3,378 and Net Loss of \$77, reflecting the items noted above.

**Table of Contents**

The recognized amounts of identifiable assets acquired and liabilities assumed in the acquisition of the Bioline Group are as follows:

	<b>July 20, 2010 (as initially reported)</b>	<b>Measurement Period Adjustments</b>	<b>July 20, 2010 (as adjusted)</b>
Fair value of assets acquired			
Cash and equivalents	\$ 3,445		\$ 3,445
Accounts receivable	1,897		1,897
Inventories	2,807		2,807
Other current assets	371	\$ (21)	350
Property, plant and equipment, net	816		816
Goodwill	13,166	(441)	12,725
Other intangible assets (estimated useful life):			
Customer relationships (10 years)	3,898		3,898
Manufacturing processes (6 years)	1,467		1,467
License agreements (approx. 8 year wtd. avg.)	718		718
Non-compete agreements (1 year)	122		122
Trade names (10 years)	995		995
	29,702	(462)	29,240
Fair value of liabilities assumed			
Accounts payable and accrued expenses	2,817	97	2,914
Deferred income tax liabilities	3,036	(559)	2,477
Total consideration paid	\$ 23,849	\$	\$ 23,849

The above estimated fair values of the assets acquired and liabilities assumed continue to be preliminary and are based on the information that was available as of the acquisition date and the subsequent filing of this Form 10-Q and are reflected in the accompanying Condensed Consolidated Balance Sheets, including retrospective adjustment of the September 30, 2010 Condensed Consolidated Balance Sheet. We believe that the information provides a reasonable basis for estimating the fair values of assets acquired and liabilities assumed, however the preliminary measurements of fair value set forth above are subject to change. We expect to complete the purchase price allocation as soon as practicable, but no later than one year from the date of acquisition.

The consolidated pro forma results of the combined entities of Meridian and the Bioline Group, had the acquisition date been October 1, 2009, are as follows for the period indicated:

	<b>Three Months Ended December 31, 2009</b>
Net Sales	\$ 45,411
Net Earnings	\$ 9,235
Diluted Earnings Per Common Share	\$ 0.22





**Table of Contents****4. Inventories**

Inventories are comprised of the following:

	<b>December 31, 2010</b>	<b>September 30, 2010</b>
Raw materials	\$ 6,876	\$ 6,221
Work-in-process	6,933	6,784
Finished goods	16,277	16,090
Gross inventory	30,086	29,095
Less: Reserves	(1,375)	(1,130)
Net inventory	\$ 28,711	\$ 27,965

As of December 31, 2010, our reserves for finished goods inventory whose shelf life may expire before sale to customers included \$160 related to influenza kits manufactured by a third-party supplier. This inventory generally has expiration dating of September 30, 2011 and a net carrying value of approximately \$1,100 at December 31, 2010. We estimated the reserve for this inventory based on our sales volumes for the influenza season immediately prior to the H1N1 pandemic, as well as an estimate of the amount of inventory in distribution channels. This inventory needs to be sold during the present influenza season, which typically runs into April, in order to allow for sale to customers before expiration. The ultimate magnitude of this year's influenza season and corresponding sales volumes will not be known until the conclusion of our fiscal quarter ended March 31, 2011.

**5. Major Customers and Segment Information**

Meridian was formed in 1976 and functions as a fully-integrated research, development, manufacturing, marketing and sales organization with primary emphasis in the field of life science. Our principal businesses are (i) the development, manufacture and distribution of diagnostic test kits primarily for gastrointestinal, viral, respiratory and parasitic infectious diseases; (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers; and (iii) the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Our reportable operating segments are U.S. Diagnostics, European Diagnostics and Life Science. The U.S. Diagnostics operating segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the U.S. and countries outside of Europe, Africa and the Middle East. The European Diagnostics operating segment consists of the sale and distribution of diagnostic test kits in Europe, Africa and the Middle East. The Life Science operating segment consists of manufacturing operations in Memphis, Tennessee; Saco, Maine; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad. The Life Science operating segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Two customers accounted for 52% and 68% of the U.S. Diagnostics operating segment third-party sales during the three months ended December 31, 2010 and 2009, respectively. Four customers accounted for 25% and 38% of the Life Science operating segment third-party sales during the three months ended December 31, 2010 and 2009, respectively.

**Table of Contents**

Segment information for the interim periods is as follows:

	<b>U.S.</b>	<b>European</b>	<b>Life</b>	<b>Eliminations(1)</b>	<b>Total</b>
	<b>Diagnostics</b>	<b>Diagnostics</b>	<b>Science</b>		
<b>Three Months Ended</b>					
<b>December 31, 2010</b>					
Net sales					
Third-party	\$ 22,650	\$ 5,929	\$ 8,684	\$	\$ 37,263
Inter-segment	2,608	4	213	(2,825)	
Operating income	8,574	753	(221)	(16)	9,090
Total assets (December 31, 2010)	129,321	36,321	90,119	(99,593)	156,168
<b>Three Months Ended</b>					
<b>December 31, 2009</b>					
Net sales					
Third-party	\$ 30,704	\$ 6,294	\$ 5,459	\$	\$ 42,457
Inter-segment	2,927	1	92	(3,020)	
Operating income	12,130	970	904	(248)	13,756
Total assets (December 31, 2009)	131,963	17,959	55,670	(50,869)	154,723

(1) Eliminations consist of inter-segment transactions.

Transactions between operating segments are accounted for at established intercompany prices for internal and management purposes with all intercompany amounts eliminated in consolidation. Total assets for the U.S. Diagnostics and Life Science operating segments include goodwill of \$1,381 and \$21,374, respectively, at December 31, 2010, and \$1,381 and \$21,644, respectively, at September 30, 2010.

**6. Intangible Assets**

A summary of our acquired intangible assets subject to amortization, as of December 31, 2010 and September 30, 2010 is as follows:

	<b>December 31, 2010</b>		<b>September 30, 2010</b>	
	<b>Gross</b>	<b>Accumulated</b>	<b>Gross</b>	<b>Accumulated</b>
	<b>Carrying</b>	<b>Amortization</b>	<b>Carrying</b>	<b>Amortization</b>
	<b>Value</b>	<b>Value</b>	<b>Value</b>	<b>Value</b>
Manufacturing technologies, core products and cell lines	\$ 11,611	\$ 7,909	\$ 11,644	\$ 7,693
Trademarks, licenses and patents	3,520	1,081	3,547	997
Customer lists and supply agreements	12,448	6,071	12,537	5,816
Non-compete agreements	124	52	126	21
	\$ 27,703	\$ 15,113	\$ 27,854	\$ 14,527

The actual aggregate amortization expense for these intangible assets for the three months ended December 31, 2010 and 2009 was \$595 and \$395, respectively.



**Table of Contents****7. Fair Value Measurements**

We use fair value measurements to value our financial assets and liabilities. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value hierarchy prioritizes inputs to valuation techniques used to measure fair value into three broad levels, which are described below:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date for assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly. These include quoted prices for identical or similar assets or liabilities in markets that are not active, that is, markets in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers, or in which little information is released publicly and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3: Unobservable inputs, developed using our estimates and assumptions, which reflect those that the market participants would use. Such inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Determining where an asset or liability falls within the hierarchy depends on the lowest level input that is significant to the fair value measurement as a whole. In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and consider counterparty credit risk in the assessment of fair value.

Financial assets and liabilities carried at fair value at December 31, 2010 and September 30, 2010 and are classified in the tables below into one of the three categories described above:

**Balances as of December 31, 2010**

	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
Money market funds	\$ 10,254	\$	\$	\$ 10,254
Total	\$ 10,254	\$	\$	\$ 10,254

**Balances as of September 30, 2010**

	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
Money market funds	\$ 10,249	\$	\$	\$ 10,249
Total	\$ 10,249	\$	\$	\$ 10,249

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*Refer to Forward Looking Statements following the Index in front of this Form 10-Q. In the discussion that follows, all amounts are in thousands (both tables and text), except per share data and percentages.*

Following is a discussion and analysis of the financial statements and other statistical data that management believes will enhance the understanding of Meridian's financial condition and results of operations. This discussion should be read in conjunction with the financial statements and notes thereto beginning on page 1.

**Table of Contents****Results of Operations**

Net earnings for the first quarter of fiscal 2011 decreased 32% to \$6,025, or \$0.15 per diluted share, from net earnings for the first quarter of fiscal 2010 of \$8,921, or \$0.22 per diluted share. This decrease reflects the combined effects of decreased sales and increased operating expenses, resulting primarily from having a full quarter of expenses from the Bioline Group, which was acquired in July 2010. Consolidated sales decreased 12% to \$37,263 for the first quarter of fiscal 2011 compared to the same period of the prior year, reflecting an approximate \$7,500 decline in influenza product sales.

Sales for the U.S. Diagnostics operating segment for the first quarter of fiscal 2011 decreased 26% compared to the first quarter of fiscal 2010, reflecting the dramatic impact on the fiscal 2010 first quarter of the novel A (H1N1) influenza outbreak and the abrupt halt of the outbreak in December 2009, along with a slight sales decrease in our *C. difficile* product family and double digit growth in our foodborne and *H. pylori* product families. First quarter 2011 sales for our European Diagnostics operating segment decreased 6% compared to the first quarter of fiscal 2010 largely due to negative currency effect, while, as a result of the Bioline Group acquisition, our Life Science segment experienced a 59% increase in sales during this period. Excluding the effect of the Bioline Group, sales of our Life Science operating segment decreased by 3% during the first quarter of fiscal 2011 compared to the first quarter of fiscal 2010, reflecting the business' ongoing dependency on the timing of customers' buying patterns.

**Revenue Overview**

Our Diagnostics operating segments provide the largest share of our consolidated revenues, 77% and 87% for the first quarters of fiscal 2011 and 2010, respectively, with the percentage decline resulting primarily from the addition of the Bioline Group to our Life Science operating segment and the impact of the influenza outbreak in 2010. Sales from our four focus families (*C. difficile*, *H. pylori*, Foodborne and Upper Respiratory) comprised 67% and 73% of our Diagnostics operating segments' revenues during the first quarters of fiscal 2011 and 2010, respectively.

Overall revenue change for the fiscal 2011 first quarter for our Diagnostics operating segments was a decrease of 23%, largely due to a relatively mild worldwide flu season in the first quarter of fiscal 2011 compared to the fiscal 2010 first quarter, including the effects on the prior year of the world-wide outbreak of novel A (H1N1) influenza. Further contributing to the first quarter year-over-year sales decline was the fact that sales of our *C. difficile* family of products continued to be negatively impacted by significant competitive pressures and ongoing confusion surrounding the various testing methods, factors which we believe are being countered by our recently-introduced *illumigene*<sup>®</sup> molecular *C. difficile* product, which offset much of the decline. Partially offsetting the effects of the declines in these products were sales increases in our *H. pylori* and foodborne families of products of 11% and 10%, respectively, compared to the first quarter of fiscal 2010. On an organic basis, which excludes the effects of currency translation, sales for our European Diagnostics operating segment increased by 1% during the first quarter, reflecting the combined effects of growth in our foodborne products category, partially offset by declines in our upper respiratory and *C. difficile* product families.

**C. difficile Products**

During the third quarter of fiscal 2010, we launched our *illumigene*<sup>®</sup> molecular *C. difficile* product in non-U.S. markets, with launch of the product into U.S. markets following in the fourth quarter of fiscal 2010, upon receiving FDA clearance. As a result, we currently have approximately 200 customer accounts and others that are evaluating our *illumigene*<sup>®</sup> molecular *C. difficile* product. We expect sales of the product, which totaled approximately \$775 in the first quarter of fiscal 2011, to continue to grow significantly throughout fiscal 2011 and recently executed an agreement with a large U.S. medical products distributor to sell the product in the U.S. market.

As a result of competitive pressures in this disease family over the last several years from new competitive products, including molecular assays, we have experienced overall declines in the sales of our *C. difficile* products. Although sales of *C. difficile* products decreased 3% for all of our Diagnostics operating segments during the first quarter of fiscal 2011, this rate of decline is a marked improvement over the double digit declines experienced during fiscal 2010 and continued improvement is expected as result of ongoing *illumigene*<sup>®</sup> molecular *C. difficile* product sales. With the launch of our molecular product, we believe we are in a unique position to offer a full line of testing solutions to our clinical laboratory customers around the world to counter the competitive pressures surrounding this market.



**Table of Contents*****Upper Respiratory Products***

During the first quarter of fiscal 2011, upper respiratory product sales for our Diagnostics operating segments decreased 72% compared to the first quarter of fiscal 2010. This dramatic sales reduction for this family of products was driven by the abrupt halt, in December 2009, of the outbreak of the novel A (H1N1) influenza virus that began to spread across the countries in the northern hemisphere during the second half of fiscal 2009. The outbreak also created an increased interest in influenza testing in European markets where rapid testing has not been traditionally performed and resulted in significant sales activity for these products during the fiscal 2010 first quarter. However, similar to U.S. markets, these sales levels have not been repeated in the fiscal 2011 first quarter, as evidenced by the approximate 42% decline in this operating segment's upper respiratory product sales on an organic basis (excluding effects of currency translation) since the first quarter of fiscal 2010.

While the severity of upcoming influenza seasons can never be predicted with complete certainty, we are neither expecting nor relying upon significant revenue contribution from influenza products during the balance of fiscal 2011.

***Foodborne Products***

During the first quarter of fiscal 2011, sales of our foodborne products increased approximately 9% for our U.S. Diagnostics operating segment and approximately 45% for our European Diagnostics operating segment on an organic basis. While first quarter foodborne comparisons were difficult due to the effects of certain distributor order patterns, as expected January sales demonstrated strong sales growth in excess of 100%, as we rebound from the first quarter order patterns.

***H. pylori Products***

During the first quarter of fiscal 2011, sales of our *H. pylori* products grew 16% for our U.S. Diagnostics operating segment. This increase continues to reflect the benefits of our partnerships with managed care companies in promoting the health and economic benefits of a test and treat strategy, and the ongoing effects of such strategy moving physician behavior away from serology-based testing toward direct antigen testing. Sales of *H. pylori* products for our European Diagnostics operating segment grew 4% on an organic basis for the fiscal 2011 first quarter, compared to the first quarter of fiscal 2010.

***Group Purchasing Organizations***

In our U.S. Diagnostics operating segment, consolidation of the U.S. healthcare industry over the last several years has led to the creation of group purchasing organizations (GPOs) that aggregate buying power for hospital groups and put pressure on our selling prices. We have multi-year supply agreements with several GPOs. During the first three months of fiscal 2011, we have experienced approximately \$550 in unfavorable price variance, as a result of these agreements. However, these agreements help secure our products with these customers and have led to new business. While in the near term this has negatively impacted gross profit, further increases in volumes are expected from these contracts. Furthermore, given the timing of entering into these agreements, the effect of the related price declines will not be reflected in the year-over-year comparisons beginning in the second quarter of fiscal 2011.

***Foreign Currency***

Sales for our European Diagnostics operating segment included the effect of less favorable currency rates, which led to currency translation losses in the amount of approximately \$435 for the first quarter of fiscal 2011, compared to \$600 of currency translation gains in the fiscal 2010 first quarter.

***Life Science Operating Segment***

Sales for our Life Science operating segment increased 59% for the first quarter of fiscal 2011 due primarily to the revenue contribution of the Bioline Group acquired in July 2010. Excluding the impact of the Bioline Group, sales for the operating segment declined 3%, reflecting the buying patterns of our two largest diagnostic manufacturing customers. Including the effect of the addition of the Bioline Group, we expect approximate 50% revenue growth for this operating segment in fiscal 2011, compared to fiscal 2010, and approximate 6% growth excluding the effects of the Bioline Group.

**Table of Contents****Significant Customers**

Two national distributors in our U.S. Diagnostics operating segment accounted for 52% and 68% of total sales for this operating segment for the first quarters of fiscal 2011 and 2010, respectively. The lower percentage of sales during the first quarter of fiscal 2011 reflects the comparative decline in the distributors' inventory stocking of influenza and other products.

Four diagnostic manufacturing customers in our Life Science operating segment accounted for 25% and 38% of total sales for this operating segment for the first quarters of fiscal 2011 and 2010, respectively. The lower percentage of sales during the first quarter of fiscal 2011 results from the addition of the Bioline Group.

**Operating Segment Revenues**

Our reportable operating segments are U.S. Diagnostics, European Diagnostics and Life Science. The U.S. Diagnostics operating segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the U.S. and countries outside of Europe, Africa and the Middle East. The European Diagnostics operating segment consists of the sale and distribution of diagnostic test kits in Europe, Africa and the Middle East. The Life Science operating segment consists of manufacturing operations in Memphis, Tennessee; Saco, Maine; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad. The Life Science operating segment also includes the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Revenues for the Diagnostics operating segments, in the normal course of business, may be affected from quarter to quarter by buying patterns of major distributors, seasonality and strength of certain diseases and foreign currency exchange rates. Revenues for the Life Science operating segment, in the normal course of business, may be affected from quarter to quarter by the timing and nature of arrangements for contract services work, which may have longer production cycles than bioresearch reagents and bulk antigens and antibodies, as well as buying patterns of major customers. We believe that the overall breadth of our product lines serves to reduce the variability in consolidated revenues.

Revenues for each of our operating segments are shown below.

	<b>Three Months Ended December 31,</b>		
	<b>2010</b>	<b>2009</b>	<b>Inc (Dec)</b>
U.S. Diagnostics	\$ 22,650	\$ 30,704	(26)%
European Diagnostics	5,929	6,294	(6)%
Life Science	8,684	5,459	59%
Consolidated	\$ 37,263	\$ 42,457	(12)%
International			
U.S. Diagnostics	\$ 1,596	\$ 1,729	(8)%
European Diagnostics	5,929	6,294	(6)%
Life Science	4,589	2,460	87%
Total	\$ 12,114	\$ 10,483	16%
% of total sales	33%	25%	





**Table of Contents****Gross Profit**

	<b>Three Months Ended December 31,</b>		
	<b>2010</b>	<b>2009</b>	<b>Change</b>
Gross Profit	\$ 23,620	\$ 25,485	(7)%
Gross Profit Margin	63%	60%	+3 points

Gross profit margin improvement for the first quarter of fiscal 2011 results primarily from the combined effects of continued operating efficiencies in our Cincinnati, Ohio diagnostic test manufacturing facility and the quarter-over-quarter decline in upper respiratory product sales. Our upper respiratory product family generally has a lower gross profit margin than our other focus product families (*C. difficile*, *H. pylori* and foodborne). Sales of upper respiratory products during the first quarter of fiscal 2011 were approximately 8% of our consolidated sales, compared to 27% of our consolidated sales during the first quarter of fiscal 2010.

Our overall operations consist of the sale of diagnostic test kits for various disease states and in alternative test formats, as well as bioresearch reagents, bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, proficiency panels, contract research and development, and contract manufacturing services. Product sales mix shifts, in the normal course of business, can cause the consolidated gross profit margin to fluctuate by several points.

**Operating Expenses**

	<b>Research &amp; Development</b>	<b>Selling &amp; Marketing</b>	<b>General &amp; Administrative</b>	<b>Total Operating Expenses</b>
<b>Q1 2010 Expenses</b>	\$ 2,078	\$ 4,887	\$ 4,764	\$ 11,729
% of Sales	5%	12%	11%	28%
Fiscal 2011 Increases (Decreases):				
U.S. Diagnostics	(46)	40	355	349
European Diagnostics		(81)	(36)	(117)
Life Science	296	841	1,432	2,569
<b>Q1 2011 Expenses</b>	\$ 2,328	\$ 5,687	\$ 6,515	\$ 14,530
% of Sales	6%	15%	17%	39%
% Increase	12%	16%	37%	24%

We continue to closely control spending for each of our operating segments.

The \$2,801 increase in all three operating expense categories results primarily from the addition of the Bioline Group's operating expenses of approximately \$2,365. Additionally, the general and administrative expenses for the U.S. Diagnostics operating segment reflect an approximate \$400 increase in stock-based compensation expense for restricted stock grants during the fiscal 2011 first quarter.

**Operating Income**

Operating income decreased 34% to \$9,090 for the first quarter of fiscal 2011, as a result of the factors discussed above.

**Table of Contents**

**Other Income and Expense**

The increase in other income, net, can primarily be attributed to the addition of the Bioline Group, as it contributed to an improvement in net currency exchange gains/losses of approximately \$165 and grant income from a foreign governmental agency of approximately \$100.

**Income Taxes**

The effective rate for income taxes was 35% for the first quarters of both fiscal 2011 and fiscal 2010. For the fiscal year ending September 30, 2011, we expect the effective tax rate to remain at approximately 35%.

**Liquidity and Capital Resources**

***Comparative Cash Flow Analysis***

Our cash flow and financing requirements are determined by analyses of operating and capital spending budgets, consideration of acquisition plans, and consideration of common share dividends. We have historically maintained a credit facility to augment working capital requirements and to respond quickly to acquisition opportunities. Our investment portfolio presently contains overnight repurchase agreements and institutional money-market mutual funds. We used \$23,849 from our investment portfolio to complete the acquisition of the Bioline Group during July 2010.

We have an investment policy that guides the holdings of our investment portfolio. Our objectives in managing the investment portfolio are to (i) preserve capital; (ii) provide sufficient liquidity to meet working capital requirements and fund strategic objectives such as acquisitions; and (iii) capture a market rate of return commensurate with market conditions and our policy's investment eligibility criteria. As we look forward, we will continue to manage the holdings of our investment portfolio with preservation of capital being the primary objective.

Except as otherwise described herein, we do not expect current conditions in the financial markets, or overall economic conditions to have a significant impact on our liquidity needs, financial condition, or results of operations. We intend to continue to fund our working capital requirements and dividends from current cash flows from operating activities. We also have additional sources of liquidity through our investment portfolio and a \$30,000 bank credit facility, if needed. To date, we have not experienced any significant deterioration in the aging of our customer accounts receivable nor in our vendors' ability to supply raw materials and services and extend normal credit terms. Our liquidity needs may change if overall economic conditions worsen and/or liquidity and credit within the financial markets remains tight for an extended period of time, and such conditions impact the collectibility of our customer accounts receivable, or impact credit terms with our vendors, or disrupt the supply of raw materials and services.

Net cash provided by operating activities increased 3% for the first quarter of fiscal 2011 to \$13,599, despite a 32% decrease in net earnings. This modest increase was primarily attributable to net working capital changes related to fluctuations in sales levels and the timing of payments with suppliers. Net cash flows from operating activities are anticipated to be adequate to fund working capital requirements and dividends during the next 12 months.

***Capital Resources***

We have a \$30,000 credit facility with a commercial bank which expires on September 15, 2012. As of January 31, 2011, there were no borrowings outstanding on this facility and we had 100% borrowing capacity available to us. We have had no borrowings outstanding under this facility during the first three months of fiscal 2011, or during the full year of fiscal 2010.

Our capital expenditures are estimated to range between approximately \$6,000 to \$9,500 for fiscal 2011, with the actual amount depending upon actual operating results and the phasing of certain projects. Such expenditures may be funded with cash and cash equivalents on hand, operating cash flows, and/or availability under the \$30,000 credit facility discussed above. Capital expenditures relate to manufacturing and other equipment of a normal and recurring nature, as well as costs associated with production line automation in Cincinnati, facilities expansions in Cincinnati and Memphis, computer system and software purchases for the Bioline Group, and instrumentation to support the ongoing *illumigene*<sup>®</sup> product launch.

**Table of Contents**

We do not utilize any special-purpose financing vehicles or have any undisclosed off balance sheet arrangements.

**Critical Accounting Policies Inventories**

Our inventories are carried at the lower of cost or market. Cost is determined on a first-in, first-out basis. We establish reserves against cost for excess and obsolete materials, finished goods whose shelf life may expire before sale to customers, and other identified exposures. Management estimates these reserves based on assumptions about future demand and market conditions. If actual demand and market conditions were to be less favorable than such estimates, additional inventory write-downs would be required and recorded in the period known. Such adjustments would negatively affect gross profit margin and overall results of operations.

As of December 31, 2010, our reserves for finished goods inventory whose shelf life may expire before sale to customers included \$160 related to influenza kits manufactured by a third-party supplier. This inventory generally has expiration dating of September 30, 2011 and a net carrying value of approximately \$1,100 at December 31, 2010. We estimated the reserve for this inventory based on our sales volumes for the influenza season immediately prior to the H1N1 pandemic, as well as an estimate of the amount of inventory in distribution channels. This inventory needs to be sold during the present influenza season, which typically runs into April, in order to allow for sale to customers before expiration. The ultimate magnitude of this year's influenza season and corresponding sales volumes will not be known until the conclusion of our fiscal quarter ended March 31, 2011.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

There have been no material changes in the Company's exposure to market risk since September 30, 2010.

**ITEM 4. CONTROLS AND PROCEDURES**

As of December 31, 2010, an evaluation was completed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) and 15d-15(b) promulgated under the Securities Exchange Act of 1934, as amended. Based on that evaluation, our management, including the CEO and CFO, concluded that our disclosure controls and procedures were effective as of December 31, 2010. There have been no changes in our internal control over financial reporting identified in connection with the evaluation of internal control that occurred during the first fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, or in other factors that could materially affect internal control subsequent to December 31, 2010.

**Table of Contents**

**PART II. OTHER INFORMATION**

**ITEM 1A. RISK FACTORS**

There have been no material changes from risk factors as previously disclosed in the Registrant's Form 10-K in response to Item 1A to Part I of Form 10-K.

**ITEM 6. EXHIBITS**

- 10.18.3 Second Amendment to Loan and Security Agreement among Meridian Bioscience, Inc., Meridian Bioscience Corporation, Omega Technologies, Inc., Meridian Life Science, Inc. and Fifth Third Bank dated December 1, 2010 (Filed herewith)
  
- 31.1 Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) (Filed herewith)
  
- 31.2 Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) (Filed herewith)
  
- 32 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Filed herewith)

**Table of Contents**

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**MERIDIAN BIOSCIENCE, INC.**

Date: February 9, 2011

/s/ Melissa A. Lueke  
Melissa A. Lueke  
Executive Vice President and  
Chief Financial Officer

Page 20